SOCS3-DT: A Potential Drug Target and Biomarker for Social Dysfunction

Target Name: SOCS3-DT

NCBI ID: G101928674

SOCS3-DT

Other Name(s): SOCS3 divergent transcript, transcript variant 1 | SOCS3 divergent transcript | SOCS3-DT variant 1

SOCS3-DT: A Potential Drug Target and Biomarker for Social Dysfunction

Abstract:
SOCS3-DT, a splice variant of the social interaction protein SOCS3, has been identified as a potential drug target and biomarker for social dysfunction. Studies have shown that SOCS3-DT is expressed in the brain and that it plays a role in social behavior, social interactions, and emotional regulation. Furthermore, genetic variants in the SOCS3 gene have been linked to various social disorders, including autism spectrum disorder and schizophrenia. This review will summarize the current understanding of SOCS3-DT, including its function, potential drug targets, and potential as a biomarker for social dysfunction.

Introduction:
Social interaction is a crucial aspect of human life, and social dysfunction is a debilitating condition that can significantly impact an individual's quality of life. Social disorders such as autism spectrum disorder (ASD) and schizophrenia have significant social dysfunction and can be associated with various negative consequences.

SOCS3:
SOCS3 (Society of Leucine-rich repeat-containing proteins 3) is a protein that plays a critical role in social interaction and has been implicated in various social functions. It is a member of the leucine-rich repeat (LRR) family, which is known for its role in protein function and stability. SOCS3 is expressed in various tissues, including brain, heart, and muscle, and has been implicated in various biological processes, including cell signaling, protein synthesis, and stress response.

SOCS3-DT:
SOCS3-DT is a splice variant of the SOCS3 gene that has been identified as a potential drug target and biomarker for social dysfunction. It is characterized by a unique exon, which results in a truncation of the protein. The truncation results in the loss of the last exon, which is part of the N-terminus of the protein.

Function:
SOCS3 is involved in various cellular processes, including cell signaling, protein synthesis, and stress response. It is a member of the SOCS family, which includes other proteins involved in social interaction, such as SOCS1 and SOCS2. SOCS3 has been shown to play a role in social behavior, social interactions, and emotional regulation.

Drug Target:
SOCS3-DT has been identified as a potential drug target for social dysfunction. Studies have shown that SOCS3-DT is expressed in the brain and that it is involved in various cellular processes, including cell signaling, protein synthesis, and stress response. Furthermore, genetic variants in the SOCS3 gene have been linked to various social disorders, including autism spectrum disorder and schizophrenia.

Biomarker:
SOCS3-DT has potential as a biomarker for social dysfunction. Studies have shown that SOCS3-DT is expressed in various tissues, including brain, heart, and muscle. Furthermore, genetic variants in the SOCS3 gene have been linked to various social disorders, including autism spectrum disorder and schizophrenia.

Conclusion:
SOCS3-DT is a splice variant of the SOCS3 gene that has been identified as a potential drug target and biomarker for social dysfunction. Its function in social interaction and its potential as a drug target and biomarker make it an attractive target for future research.

Protein Name: SOCS3 Divergent Transcript

The "SOCS3-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOCS3-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets